Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Up 14.8% in April

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 510,400 shares, a growth of 14.8% from the March 31st total of 444,600 shares. Based on an average trading volume of 502,300 shares, the short-interest ratio is currently 1.0 days. Approximately 2.9% of the shares of the company are sold short.

Institutional Trading of Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Vontobel Holding Ltd. acquired a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 12,000 shares of the company’s stock, valued at approximately $30,000. Vontobel Holding Ltd. owned approximately 0.06% of Cardio Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Price Performance

NASDAQ CDIO traded up $0.01 on Monday, reaching $0.70. 541,797 shares of the stock were exchanged, compared to its average volume of 935,276. Cardio Diagnostics has a one year low of $0.17 and a one year high of $3.56. The company’s 50-day simple moving average is $1.30 and its two-hundred day simple moving average is $1.54.

Wall Street Analysts Forecast Growth

Separately, Benchmark decreased their target price on Cardio Diagnostics from $4.00 to $1.35 and set a “speculative buy” rating on the stock in a report on Friday, April 19th.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.